Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Non-Current Assets (2016 - 2025)

Heron Therapeutics (HRTX) has disclosed Non-Current Assets for 14 consecutive years, with $17.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non-Current Assets fell 26.2% year-over-year to $17.8 million, compared with a TTM value of $81.4 million through Dec 2025, down 25.06%, and an annual FY2025 reading of $17.8 million, down 26.2% over the prior year.
  • Non-Current Assets was $17.8 million for Q4 2025 at Heron Therapeutics, down from $19.6 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $51.3 million in Q4 2021 and bottomed at $17.8 million in Q4 2025.
  • Average Non-Current Assets over 5 years is $34.8 million, with a median of $35.6 million recorded in 2023.
  • The sharpest move saw Non-Current Assets soared 32.95% in 2022, then decreased 28.46% in 2024.
  • Year by year, Non-Current Assets stood at $51.3 million in 2021, then decreased by 11.25% to $45.5 million in 2022, then dropped by 25.89% to $33.7 million in 2023, then fell by 28.46% to $24.1 million in 2024, then dropped by 26.2% to $17.8 million in 2025.
  • Business Quant data shows Non-Current Assets for HRTX at $17.8 million in Q4 2025, $19.6 million in Q3 2025, and $21.2 million in Q2 2025.